We are pioneering a groundbreaking new immunotherapy. It has the potential to fundamentally change the way we treat skin cancer. Cancer cells manage to survive and grow because they escape the body’s natural defenses. They do so by producing signals that confuse the immune system. These signals are what is called the tumor micro-environment.
Using our advanced proprietary microneedle-Duo (M-Duo) Technology®, we can remove the signals produced by the tumor. This non-invasive and mild therapy stimulates an immune response that reduces disease progression and mediates tumor destruction. We are currently at an early R&D stage, and we partner and collaborate with leading institutions and innovative companies to realize the full potential of our cutting-edge M-Duo Technology®.
IMcoMET has developed a technology that allows to locally control the composition of the fluid that surrounds the cells, called the interstitial fluid. This fluid contains most of the signals that cells use to communicate with each other. These signals are very important to maintain a healthy skin, and are one of the first things that go wrong in cancer.
We are using our unique system to pioneer a novel approach for cancer treatment and immunotherapy.
Every new technology comes with new tools and instruments that embed it. We are developing a set of tools for patients diagnostics and cancer research that will help reduce patient's burden and accelerate the research for treatment personalization.
Explore the different ways our technology can be applied.
We are currently developing a set of pre-clinical R&D tools based on our M-Duo Technology® that will provide a new type of data and therefore new insight into tissue biology in health and disease.
By allowing continuous access to the heart of the tumor, our technology offers an unprecedented way to refine molecular diagnostic for precision medicine, and monitoring treatment efficacy.
We are pioneering a novel concept for skin cancer treatment that relies on physically removing the signals that the tumor produces to escape the patient's immune system.
